Pharma Focus Asia

Erimos Pharmaceuticals Announces Phase I Oral Study of Terameprocol (EM-1421)

Wednesday, June 27, 2018

Erimos Pharmaceuticals, LLC announced today, in collaboration with Adult Brain Tumor Consortium (ABTC) and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, initiation of a multi-center phase I clinical study of their lead compound, terameprocol (EM-1421) in patients with High Grade Glioma (Grade III or IV). The primary objectives are to determine the safe dose, schedule and tumor uptake of terameprocol administered orally. Secondary endpoints include toxicity, pharmacokinetics and response. This oral study follows completion of a prior phase I trial conducted by the New Approaches to Brain Tumor Therapy Consortium that administered terameprocol intravenously to this patient population.

“We are extremely pleased with our development progress at this stage. A pharmacodynamic study in animals found low toxicity and demonstrated that terameprocol administered orally has the potential to achieve sustained plasma concentration to allow continued suppression of Sp-1 regulated genes and proteins that are over-expressed in cancer; such as survivin, cdc2, VEGF and AKT. Additional oral clinical studies are planned for other solid tumor and hematological malignancies, based on previous phase 1 clinical trials conducted with intravenous terameprocol,” stated Jeffrey Khoo, CEO and Chairman of the Board of Erimos Pharmaceuticals, LLC.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024